Skip to main content

Table 1 Characteristics of HIV-1 infected women

From: CD4+T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs

Patients no.

Initiation of antiretroviral treatment

(days before delivery)

Duration of lactation until sampling (days)

Antiretroviral regimen

Treatment at time of sampling

CD4+ T cell counts/mm3

HIV-1 RNA level (copies/ml)

      

plasma

Breast milk

1

15

54

ARTa

Ongoing

NT

ND b

NT

2

18

65

Short-course prophylaxisc

Withdrawal since 65 days

400

1776

ND

3

34

33

ART

Ongoing

762

ND

ND

4

35

11

Short-course prophylaxis

Withdrawal since 11 days

521

12,878

ND

5

38

14

Short-course prophylaxis

Withdrawal since 14 days

270

83,547

ND

6

26

55

Short-course prophylaxis

Withdrawal since 55 days

646

ND

ND

7

47

57

Short-course prophylaxis

Withdrawal since 57 days

658

6,790

ND

8

32

50

ART

Ongoing

305

34,937

4,062

9

17

29

ART

Ongoing

416

ND

ND

10

65

91

Short-course prophylaxis

Withdrawal since 91 days

628

50,036

772

11

58

77

Short-course prophylaxis

Withdrawal since 77 days

618

ND

190

12

15

52

ART

Ongoing

444

ND

ND

13

69

21

ART

Ongoing

533

ND

ND

14

46

9

Short-course prophylaxis

Withdrawal since 9 days

688

1,049

145

15

31

15

Short-course prophylaxis

Withdrawal since 15 days

384

4,526

308

  1. aART, antiretroviral therapy.
  2. bThreshold: 300 copies/ml plasma and 60 copies/ml for breast milk.
  3. cShort-course perinatal prophylaxis (zidovudine until delivery and a single-dose of nevirapine during labor).
  4. NT: not tested.
  5. ND: not detected, < threshold.